# Mistras Group, Inc.: financial statements, quarterly

MG · NYSE · CIK 1436126 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mg.md) · [Financials](/companies/mg/financials.md) · [Filings](/companies/mg/filings.md) · [Insiders](/companies/mg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [179](/filings/0001436126-24-000065.md) | [182](/filings/0001436126-24-000025.md) | [184](/filings/0001436126-25-000034.md) | [190](/filings/0001436126-25-000068.md) | [183](/filings/0001628280-25-050063.md) | [173 d](/filings/0001628280-26-016765.md) | [162](/filings/0001628280-26-031968.md) | [185](/filings/0001628280-26-055351.md) | [196](/filings/0001628280-25-050063.md) | [181 d](/filings/0001628280-26-016765.md) | [169](/filings/0001628280-26-031968.md) | [193](/filings/0001628280-26-055351.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | [54.4](/filings/0001436126-24-000065.md) | [53.6](/filings/0001436126-24-000025.md) | [46.2](/filings/0001436126-25-000034.md) | [51.3](/filings/0001436126-25-000068.md) | [48.9](/filings/0001628280-25-050063.md) | [45.8 d](/filings/0001628280-26-016765.md) | [40.9](/filings/0001628280-26-031968.md) | [53.9](/filings/0001628280-26-055351.md) | [58.2](/filings/0001628280-25-050063.md) | [51.5 d](/filings/0001628280-26-016765.md) | [44.7](/filings/0001628280-26-031968.md) | [56.4](/filings/0001628280-26-055351.md) |
| Research and development | $m | [0.4](/filings/0001436126-24-000065.md) | [0.3 d](/filings/0001628280-26-016765.md) | [0.3](/filings/0001436126-25-000034.md) | [0.2](/filings/0001436126-25-000068.md) | [0.2](/filings/0001628280-25-050063.md) | [0.3 d](/filings/0001628280-26-016765.md) | [0.3](/filings/0001628280-26-031968.md) | [0.3](/filings/0001628280-26-055351.md) | [0.2](/filings/0001628280-25-050063.md) | [0.3 d](/filings/0001628280-26-016765.md) | [0.2](/filings/0001628280-26-031968.md) | [0.2](/filings/0001628280-26-055351.md) |
| Selling, general and administrative | $m | [39.5](/filings/0001436126-24-000065.md) | [23.4 d](/filings/0001628280-26-016765.md) | [36.3](/filings/0001436126-25-000034.md) | [36.2](/filings/0001436126-25-000068.md) | [33.2](/filings/0001628280-25-050063.md) | [29.8 d](/filings/0001628280-26-016765.md) | [35.7](/filings/0001628280-26-031968.md) | [39.8](/filings/0001628280-26-055351.md) | [33.5](/filings/0001628280-25-050063.md) | [31.0 d](/filings/0001628280-26-016765.md) | [37.0](/filings/0001628280-26-031968.md) | [38.7](/filings/0001628280-26-055351.md) |
| Operating income | $m | [(4.7)](/filings/0001436126-24-000065.md) | [0.7](/filings/0001436126-24-000025.md) | [5.6](/filings/0001436126-25-000034.md) | [12.0](/filings/0001436126-25-000068.md) | [11.9](/filings/0001628280-25-050063.md) | [10.5 d](/filings/0001628280-26-016765.md) | [(1.0)](/filings/0001628280-26-031968.md) | [8.4](/filings/0001628280-26-055351.md) | [20.4](/filings/0001628280-25-050063.md) | [12.8 d](/filings/0001628280-26-016765.md) | [4.7](/filings/0001628280-26-031968.md) | [12.9](/filings/0001628280-26-055351.md) |
| Interest expense | $m | [4.2](/filings/0001436126-23-000052.md) | [4.7 d](/filings/0001436126-24-000025.md) | [4.4](/filings/0001436126-24-000035.md) | [4.4](/filings/0001436126-25-000068.md) | [4.3](/filings/0001628280-25-050063.md) | [3.9 d](/filings/0001628280-26-016765.md) | [3.3](/filings/0001628280-26-031968.md) | [4.2](/filings/0001628280-26-055351.md) | [3.4](/filings/0001628280-25-050063.md) | [3.7 d](/filings/0001628280-26-016765.md) | [2.9](/filings/0001628280-26-031968.md) | [4.1](/filings/0001628280-26-055351.md) |
| Income tax | $m | [1.5](/filings/0001436126-24-000065.md) | [(1.4) d](/filings/0001628280-26-016765.md) | [0.1](/filings/0001436126-25-000034.md) | [1.2](/filings/0001436126-25-000068.md) | [2.6](/filings/0001628280-25-050063.md) | [1.4 d](/filings/0001628280-26-016765.md) | [(1.2)](/filings/0001628280-26-031968.md) | [1.1](/filings/0001628280-26-055351.md) | [3.8](/filings/0001628280-25-050063.md) | [1.9 d](/filings/0001628280-26-016765.md) | [0.4](/filings/0001628280-26-031968.md) | [2.3](/filings/0001628280-26-055351.md) |
| Net income | $m | [(10.3)](/filings/0001436126-24-000065.md) | [(2.5)](/filings/0001436126-24-000025.md) | [1.0](/filings/0001436126-25-000034.md) | [6.4](/filings/0001436126-25-000068.md) | [6.4](/filings/0001628280-25-050063.md) | [5.2 d](/filings/0001628280-26-016765.md) | [(3.2)](/filings/0001628280-26-031968.md) | [3.0](/filings/0001628280-26-055351.md) | [13.1](/filings/0001628280-25-050063.md) | [3.9 d](/filings/0001628280-26-016765.md) | [2.4](/filings/0001628280-26-031968.md) | [7.6](/filings/0001628280-26-055351.md) |
| Diluted EPS | $ per share | not reported | not reported | [0.03](/filings/0001436126-25-000034.md) | [0.20](/filings/0001436126-25-000068.md) | [0.20](/filings/0001628280-25-050063.md) | not reported | [(0.10)](/filings/0001628280-26-031968.md) | [0.10](/filings/0001628280-26-055351.md) | [0.41](/filings/0001628280-25-050063.md) | not reported | [0.07](/filings/0001628280-26-031968.md) | [0.23](/filings/0001628280-26-055351.md) |
| Basic EPS | $ per share | not reported | not reported | [0.03](/filings/0001436126-25-000034.md) | [0.21](/filings/0001436126-25-000068.md) | [0.21](/filings/0001628280-25-050063.md) | not reported | [(0.10)](/filings/0001628280-26-031968.md) | [0.10](/filings/0001628280-26-055351.md) | [0.42](/filings/0001628280-25-050063.md) | not reported | [0.08](/filings/0001628280-26-031968.md) | [0.24](/filings/0001628280-26-055351.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [12.8](/filings/0001436126-23-000052.md) | [17.6](/filings/0001436126-25-000026.md) | [16.9](/filings/0001436126-24-000035.md) | [17.2](/filings/0001436126-24-000052.md) | [20.4](/filings/0001436126-24-000065.md) | [18.3](/filings/0001628280-26-016765.md) | [18.5](/filings/0001436126-25-000034.md) | [20.0](/filings/0001436126-25-000068.md) | [27.8](/filings/0001628280-25-050063.md) | [28.0](/filings/0001628280-26-055351.md) | [25.0](/filings/0001628280-26-031968.md) | [22.0](/filings/0001628280-26-055351.md) |
| Current assets | $m | [183](/filings/0001436126-23-000052.md) | [180](/filings/0001436126-25-000026.md) | [187](/filings/0001436126-24-000035.md) | [193](/filings/0001436126-24-000052.md) | [193](/filings/0001436126-24-000065.md) | [172](/filings/0001628280-26-016765.md) | [176](/filings/0001436126-25-000034.md) | [213](/filings/0001436126-25-000068.md) | [237](/filings/0001628280-25-050063.md) | [216](/filings/0001628280-26-055351.md) | [211](/filings/0001628280-26-031968.md) | [219](/filings/0001628280-26-055351.md) |
| Total assets | $m | [537](/filings/0001436126-23-000052.md) | [535](/filings/0001436126-25-000026.md) | [542](/filings/0001436126-24-000035.md) | [548](/filings/0001436126-24-000052.md) | [552](/filings/0001436126-24-000065.md) | [523](/filings/0001628280-26-016765.md) | [527](/filings/0001436126-25-000034.md) | [571](/filings/0001436126-25-000068.md) | [596](/filings/0001628280-25-050063.md) | [579](/filings/0001628280-26-055351.md) | [573](/filings/0001628280-26-031968.md) | [584](/filings/0001628280-26-055351.md) |
| Current liabilities | $m | [111](/filings/0001436126-23-000052.md) | [117](/filings/0001436126-25-000026.md) | [115](/filings/0001436126-24-000035.md) | [115](/filings/0001436126-24-000052.md) | [115](/filings/0001436126-24-000065.md) | [115](/filings/0001628280-26-016765.md) | [118](/filings/0001436126-25-000034.md) | [128](/filings/0001436126-25-000068.md) | [126](/filings/0001628280-25-050063.md) | [124](/filings/0001628280-26-055351.md) | [117](/filings/0001628280-26-031968.md) | [128](/filings/0001628280-26-055351.md) |
| Total liabilities | $m | [351](/filings/0001436126-23-000052.md) | [344](/filings/0001436126-25-000026.md) | [355](/filings/0001436126-24-000035.md) | [355](/filings/0001436126-24-000052.md) | [346](/filings/0001436126-24-000065.md) | [324](/filings/0001628280-26-016765.md) | [328](/filings/0001436126-25-000034.md) | [355](/filings/0001436126-25-000068.md) | [368](/filings/0001628280-25-050063.md) | [343](/filings/0001628280-26-055351.md) | [339](/filings/0001628280-26-031968.md) | [344](/filings/0001628280-26-055351.md) |
| Long-term debt | $m | [185](/filings/0001436126-23-000052.md) | [181](/filings/0001436126-25-000026.md) | [189](/filings/0001436126-24-000035.md) | [190](/filings/0001436126-24-000052.md) | [179](/filings/0001436126-24-000065.md) | [158](/filings/0001628280-26-016765.md) | [160](/filings/0001436126-25-000034.md) | [176](/filings/0001436126-25-000068.md) | [189](/filings/0001628280-25-050063.md) | [165](/filings/0001628280-26-055351.md) | [168](/filings/0001628280-26-031968.md) | [159](/filings/0001628280-26-055351.md) |
| Current portion of debt | $m | [8.4](/filings/0001436126-23-000052.md) | [8.9](/filings/0001436126-25-000026.md) | [9.5](/filings/0001436126-24-000035.md) | [10.0](/filings/0001436126-24-000052.md) | [10.7](/filings/0001436126-24-000065.md) | [11.6](/filings/0001628280-26-016765.md) | [12.4](/filings/0001436126-25-000034.md) | [13.1](/filings/0001436126-25-000068.md) | [13.0](/filings/0001628280-25-050063.md) | [12.8](/filings/0001628280-26-055351.md) | [12.9](/filings/0001628280-26-031968.md) | [12.8](/filings/0001628280-26-055351.md) |
| Shareholders' equity | $m | [185](/filings/0001436126-23-000052.md) | [190](/filings/0001436126-25-000026.md) | [187](/filings/0001436126-24-000035.md) | [193](/filings/0001436126-24-000052.md) | [205](/filings/0001436126-24-000065.md) | [199](/filings/0001628280-26-016765.md) | [199](/filings/0001436126-25-000034.md) | [216](/filings/0001436126-25-000068.md) | [227](/filings/0001628280-25-050063.md) | [235](/filings/0001628280-26-055351.md) | [233](/filings/0001628280-26-031968.md) | [240](/filings/0001628280-26-055351.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.6) d](/filings/0001436126-24-000065.md) | [16.1 d](/filings/0001628280-26-016765.md) | [0.6](/filings/0001436126-25-000034.md) | [4.5 d](/filings/0001436126-25-000068.md) | [19.4 d](/filings/0001628280-25-050063.md) | [25.7 d](/filings/0001628280-26-016765.md) | [5.6](/filings/0001628280-26-031968.md) | [(9.3) d](/filings/0001628280-26-055351.md) | [4.5 d](/filings/0001628280-25-050063.md) | [32.1 d](/filings/0001628280-26-016765.md) | [2.8](/filings/0001628280-26-031968.md) | [14.9 d](/filings/0001628280-26-055351.md) |
| Capital expenditure | $m | [4.6 d](/filings/0001436126-24-000065.md) | [6.5 d](/filings/0001628280-26-016765.md) | [4.8](/filings/0001436126-25-000034.md) | [4.8 d](/filings/0001436126-25-000068.md) | [4.7 d](/filings/0001628280-25-050063.md) | [3.6 d](/filings/0001628280-26-016765.md) | [4.6](/filings/0001628280-26-031968.md) | [5.4 d](/filings/0001628280-26-055351.md) | [8.5 d](/filings/0001628280-25-050063.md) | [6.1 d](/filings/0001628280-26-016765.md) | [6.0](/filings/0001628280-26-031968.md) | [4.8 d](/filings/0001628280-26-055351.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [30.2](/filings/0001436126-23-000052.md) | [30.0](/filings/0001436126-24-000035.md) | [30.7](/filings/0001436126-24-000052.md) | [30.4](/filings/0001436126-24-000065.md) | [31.4](/filings/0001436126-25-000034.md) | [31.3](/filings/0001436126-25-000068.md) | [31.7](/filings/0001628280-25-050063.md) | [31.1](/filings/0001628280-26-031968.md) | [31.7](/filings/0001628280-26-055351.md) | [31.9](/filings/0001628280-25-050063.md) | [32.7](/filings/0001628280-26-031968.md) | [32.9](/filings/0001628280-26-055351.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 31,849,893 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001628280-26-055351.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.